While Bay Area drug company hosts shareholder meeting, AHF spotlights Gilead’s
ongoing illegal tactics to maximize profit and greed
LOS ANGELES (May 3, 2023) – AIDS Healthcare Foundation (AHF), the world’s largest HIV and AIDS healthcare provider, continued to expose Gilead Sciences’ despicable greed, as the company – maker of key HIV, hepatitis C, and COVID-19 drugs – hosted its virtual Annual General Meeting (AGM) Wednesday morning. Gilead keeps racking up exorbitant profits while restricting access to lifesaving medications.
In 2022, Gilead became one of 20 drug manufacturers to place unlawful restrictions on 340B contract pharmacy programs, a move that greatly reduces the number of prescriptions that nonprofit safety net care providers can fill for patients and clients.
In January of this year, AHF President Michael Weinstein wrote to Gilead CEO Daniel O’Day, asking Gilead to, “…return 340B drug discount savings entitled to nonprofit providers.” The letter (available at AHF’s www.gilead.org website) added the following:
“For ourselves, and on behalf of other impacted covered entities, we demand:
- Pricing equal to the lowest price paid by state ADAPs either individually or through negotiation with National Association of State and Territorial AIDS Directors.
- Restoration of the Advancing Access Medication Assistance Program terms that were in effect prior to January 1, 2022.
- Rollback of the 340B price increases that exceeded the rate of reimbursement increases over the past two years.
- Restoration of the sub-ceiling pricing for Descovy that was available to all covered entities prior to January 1, 2022.”
To date, AHF has received no reply from Gilead or Mr. O’Day.